Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-center, randomized, double-blind, double-dummy, active and placebo-controlled, five-period crossover trial of intranasal morphine [Egalet-001] versus MS Contin for the treatment of pain in non-dependent, recreational opioid users [Category 3 abuse-deterrent intranasal HAL study]

Trial Profile

Single-center, randomized, double-blind, double-dummy, active and placebo-controlled, five-period crossover trial of intranasal morphine [Egalet-001] versus MS Contin for the treatment of pain in non-dependent, recreational opioid users [Category 3 abuse-deterrent intranasal HAL study]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Morphine (Primary) ; Morphine
  • Indications Pain
  • Focus Pharmacodynamics
  • Sponsors Zyla Life Sciences
  • Most Recent Events

    • 15 Dec 2017 According to an Egalet Corporation media release, this data was previously excluded from the label at original new drug application (NDA) approval due to exclusivity granted to another company. The final approval is expected to be granted when the exclusivity period expires on October 2, 2018.
    • 15 Dec 2017 According to an Egalet Corporation media release, Based on the results of this trial, the US FDA has granted tentative approval for an expanded label for ARYMO ER (morphine sulfate) extended-release (ER) tablets C-II for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
    • 20 May 2017 Results of this and another phase I study presented at the 36th Annual Scientific Meeting of the American Pain Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top